The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)

We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.

[1]  R. Küppers,et al.  Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[2]  E. Terpos,et al.  Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. , 2019, Clinical lymphoma, myeloma & leukemia.

[3]  R. Ambinder,et al.  Hodgkin lymphoma: A review and update on recent progress , 2018, CA: a cancer journal for clinicians.

[4]  N. Bartlett,et al.  SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma , 2018, Clinical lymphoma, myeloma & leukemia.

[5]  M. Ratajczak,et al.  Mannan binding lectin triggers mobilization of hematopoietic stem cells , 2017, Oncotarget.

[6]  K. Brigle,et al.  Pathobiology and Diagnosis of Multiple Myeloma. , 2017, Seminars in oncology nursing.

[7]  E. Terpos.  Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. , 2017, Clinical lymphoma, myeloma & leukemia.

[8]  J. Lambert,et al.  Non-Hodgkin lymphoma , 2017, Medicine.

[9]  S. Thiel,et al.  Lectin complement pathway proteins in healthy individuals , 2017, Clinical and experimental immunology.

[10]  A. Chukhlovin,et al.  Time course of immune recovery and viral reactivation following hematopoietic stem cell transplantation , 2016 .

[11]  E. Weissinger,et al.  Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation , 2016, Front. Immunol..

[12]  M. Ratajczak,et al.  Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades , 2016, Leukemia.

[13]  K. Ohtani,et al.  The collectins CL-L1, CL-K1 and CL-P1, and their roles in complement and innate immunity. , 2016, Immunobiology.

[14]  P. Hari,et al.  Recent advances in understanding multiple myeloma , 2016, F1000Research.

[15]  Namarta Kalia,et al.  A comprehensive in silico analysis of non-synonymous and regulatory SNPs of human MBL2 gene , 2016, SpringerPlus.

[16]  G. Castaldo,et al.  Biological role of mannose binding lectin: From newborns to centenarians. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[17]  Mitchell J. Machiela,et al.  LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..

[18]  M. Mikulska,et al.  Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients , 2015, Mediterranean journal of hematology and infectious diseases.

[19]  M. Bornhäuser,et al.  Multiple myeloma , 2015, The Lancet.

[20]  S. Thiel,et al.  Structural insights into the initiating complex of the lectin pathway of complement activation. , 2015, Structure.

[21]  P. Gastmeier,et al.  Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. , 2014, The Lancet. Oncology.

[22]  K. Skjoedt,et al.  Calcium-sensitive immunoaffinity chromatography: Gentle and highly specific retrieval of a scarce plasma antigen, collectin-LK (CL-LK). , 2014, Journal of immunological methods.

[23]  J. Szemraj,et al.  Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours , 2014, Cancer Immunology, Immunotherapy.

[24]  J. Stevenson,et al.  Multiple myeloma: a review , 2014 .

[25]  M. Ratajczak,et al.  Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs) , 2014, Leukemia.

[26]  D. Turner,et al.  Epidemiology of non-Hodgkin lymphoma. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[27]  D. Kilpatrick,et al.  Mannan-binding lectin in malignancy. , 2013, Molecular immunology.

[28]  H. Nielsen,et al.  Investigations on Collectin Liver 1* , 2013, The Journal of Biological Chemistry.

[29]  David C. Linch,et al.  Non-Hodgkin's lymphoma , 2013 .

[30]  Theodore R Holford,et al.  Polymorphisms in pattern‐recognition genes in the innate immunity system and risk of non‐Hodgkin lymphoma , 2013, Environmental and molecular mutagenesis.

[31]  J. Armitage,et al.  Non-Hodgkin lymphoma , 2012, The Lancet.

[32]  D. Linch,et al.  Hodgkin's lymphoma in adults , 2012, The Lancet.

[33]  J. Vaupel,et al.  Activity of mannose‐binding lectin in centenarians , 2012, Aging cell.

[34]  Rami Y. Haddad,et al.  Infections in hematological malignancies. , 2012, Disease-a-month : DM.

[35]  Krista A. Zanetti,et al.  3'-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. , 2012, Cancer research.

[36]  M. Hibberd,et al.  Mannose-Binding Lectin 2 Polymorphisms Do Not Influence Frequency or Type of Infection in Adults with Chemotherapy Induced Neutropaenia , 2012, PloS one.

[37]  D. Armstrong,et al.  Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  M. Czerwionka-Szaflarska,et al.  Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel disease , 2011, Scandinavian journal of gastroenterology.

[39]  K. Warzocha,et al.  Diagnosis and treatment of non-Hodgkin lymphomas , 2011 .

[40]  A. Simon,et al.  Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose‐binding lectin‐associated serine protease‐2 (MASP‐2) , 2009, Pediatric blood & cancer.

[41]  John D Lambris,et al.  Is complement good or bad for cancer patients? A new perspective on an old dilemma. , 2009, Trends in immunology.

[42]  M. Matsushita,et al.  Mannan-binding lectin-associated serine protease-2 (MASP-2) in a large cohort of neonates and its clinical associations. , 2009, Molecular immunology.

[43]  M. Matsushita,et al.  Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates. , 2009, Molecular immunology.

[44]  C. D. de Groot,et al.  Mannose-binding lectin genotypes are associated with shorter gestational age. An evolutionary advantage of low MBL production genotypes? , 2008, Molecular immunology.

[45]  C. Mullighan,et al.  Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. , 2006, Blood.

[46]  Brian Staats,et al.  The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women. , 2006, Carcinogenesis.

[47]  S. Thiel,et al.  MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation , 2006, Bone Marrow Transplantation.

[48]  K. Kidd,et al.  Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. , 2006, Human molecular genetics.

[49]  S. Thiel,et al.  Chemotherapy‐related infections in patients with multiple myeloma: associations with mannan‐binding lectin genotypes , 2006, European journal of haematology.

[50]  S. Chanock,et al.  An analysis of genetic variation across the MBL2 locus in Dutch Caucasians indicates that 3′ haplotypes could modify circulating levels of mannose-binding lectin , 2005, Human Genetics.

[51]  P. Garred,et al.  The 'involution' of mannose-binding lectin. , 2005, Human molecular genetics.

[52]  S. Inaba,et al.  Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT , 2005, Genes and Immunity.

[53]  C. van Broeckhoven,et al.  novoSNP, a novel computational tool for sequence variation discovery. , 2005, Genome research.

[54]  S. Chanock,et al.  Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection , 2004, Genes and Immunity.

[55]  J. Szemraj,et al.  Mannan‐binding lectin insufficiency in children with recurrent infections of the respiratory system , 2004, Clinical and experimental immunology.

[56]  K. Hajela,et al.  Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. , 2004, Molecular immunology.

[57]  S. Thiel,et al.  Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. , 2003, Journal of immunological methods.

[58]  M. Turner,et al.  No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy‐related infections , 2003, Clinical and experimental immunology.

[59]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[60]  M. Christiansen,et al.  Low levels of mannose‐binding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy , 2003, European journal of haematology.

[61]  S. Pileri,et al.  Hodgkin's lymphoma: the pathologist's viewpoint. , 2002, Journal of clinical pathology.

[62]  S. Thiel,et al.  An assay for the mannan-binding lectin pathway of complement activation. , 2001, Journal of immunological methods.

[63]  S. Thiel,et al.  Association between deficiency of mannose-binding lectin and severe infections after chemotherapy , 2001, The Lancet.

[64]  E. Yuliwati,et al.  A Review , 2019, Current Trends and Future Developments on (Bio-) Membranes.

[65]  P. Sonneveld,et al.  Multiple myeloma , 2017, Nature Reviews Disease Primers.

[66]  M. Turner,et al.  Mannan-binding lectin genotypes and genotype-phenotype relationships in a large cohort of Polish neonates. , 2009, Human immunology.